Passage Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PASG Nasdaq 2836 www.passagebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Passage Bio, Inc.

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update - Jun 23rd, 2025 5:00 am
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - May 13th, 2025 5:00 am
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Mar 7th, 2025 10:00 am
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights - Mar 4th, 2025 5:00 am
Passage Bio to Participate in Upcoming Investor Conferences - Feb 26th, 2025 5:00 am
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates - Jan 10th, 2025 5:00 am
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely? - Dec 29th, 2024 5:20 am
Passage Bio assumed with an Outperform at Wedbush - Nov 30th, 2024 4:55 am
Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating - Nov 29th, 2024 7:00 am
Passage Bio Achieves Milestones in Gene Therapy Trials - Nov 14th, 2024 5:29 am
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - Nov 13th, 2024 5:00 am
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference - Nov 6th, 2024 5:00 am
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference - Oct 24th, 2024 5:00 am
Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc - Sep 23rd, 2024 7:36 pm
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference - Sep 23rd, 2024 5:00 am
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - Sep 18th, 2024 11:25 pm
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024) - Sep 16th, 2024 5:00 am
Passage Bio Welcomes Tom Kassberg to Board of Directors - Sep 10th, 2024 5:52 am
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference - Aug 30th, 2024 5:00 am
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - Aug 8th, 2024 5:00 am